Interestingly, in many cancers displaying MAPK hyperactivation, including those harboring RAS mutations, the administration of MEK1/2 inhibitors is poorly effective, as it interrupts negative feedbacks reverberating from the MAPK pathway to tyrosine kinase receptors. This evidence concerns the gene NTRK1 and cancer.